TARGET-HF Trial: Unveiling How SGLT2 Inhibitors Protect the Heart in Diabetes and Heart Failure Patients

What Is the TARGET-HF Trial and Why Does It Matter?

The TARGET-HF trial represents a significant effort to unravel the cardioprotective mechanisms of SGLT2 inhibitors in a high-risk population with both heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM). While previous clinical trials have established the cardiovascular benefits of SGLT2 inhibitors, including reduced hospitalization rates and mortality, the precise mechanisms underpinning these favorable outcomes remain incompletely understood. The TARGET-HF trial specifically investigates how tofogliflozin, an SGLT2 inhibitor, affects cardiac sympathetic activity as measured through I-123 metaiodobenzylguanidine (MIBG) scintigraphy in patients with this challenging comorbidity profile. This innovative approach may provide crucial insights into one potential pathway through which SGLT2 inhibitors exert their cardioprotective effects beyond glycemic control. The trial's focus on cardiac sympathetic activity is particularly relevant given that sympathetic overactivation represents a key pathophysiological feature of HFrEF that contributes significantly to disease progression and adverse outcomes.

How Is the Study Designed and Evaluated?

The study employs a single-arm prospective design, administering tofogliflozin 20 mg daily for 24 weeks to 50 patients across five Japanese university hospitals. The decision to utilize a single-arm design rather than including a control group reflects ethical considerations regarding the established benefits of SGLT2 inhibitors in HFrEF management, which are now incorporated into guideline-directed therapy. The primary endpoint—change in delayed heart-to-mediastinum ratio (HMR) on I-123 MIBG scintigraphy from baseline to 24 weeks—was selected based on its stability, reliability, and proven prognostic value in heart failure patients. This parameter effectively quantifies cardiac sympathetic nerve function, with improvements potentially indicating reduced sympathetic hyperactivity. Key secondary endpoints include changes in early HMR and washout rate on MIBG imaging, along with comprehensive echocardiographic parameters and an extensive panel of biomarkers reflecting glycemic control, lipid metabolism, renal function, inflammation, and neurohumoral activation. This multi-faceted approach allows for a thorough investigation of the potential mechanisms through which tofogliflozin might confer cardioprotection in this specific patient population.

The TARGET-HF trial's rigorous methodology includes standardized I-123 MIBG scintigraphy protocols with semi-automated quantification and central image review to ensure consistency and reliability. The investigators have implemented measures to account for variations in collimator sensitivity through standardized conversion coefficients. The sample size calculation is based on anticipated changes in delayed HMR, with assumptions derived from previous studies of standard heart failure therapies. Statistical analyses will be performed primarily using the per-protocol set, with sensitivity analyses using the full analysis set to ensure robustness of findings. Subgroup analyses stratified by age, NYHA functional class, body mass index, baseline delayed HMR, left ventricular ejection fraction, estimated glomerular filtration rate, and presence of comorbidities or concomitant medications will provide insights into potential differential effects across patient subpopulations. The comprehensive safety monitoring throughout the study period will further contribute to the risk-benefit assessment of tofogliflozin in this vulnerable patient group.

What Mechanisms Underlie SGLT2 Inhibitors’ Cardiac Benefits?

The investigators hypothesize that tofogliflozin administration will significantly improve delayed HMR, indicating reduced cardiac sympathetic activity through multiple potential mechanisms. These include decreased insulin and leptin levels, improved insulin sensitivity, reduced blood glucose levels, attenuated inflammation, and hemodynamic effects that reduce cardiac preload and afterload. Additionally, SGLT2 inhibitors may optimize cardiac energy metabolism by increasing ketone body production, which provides more efficient energy substrates for the heart than fatty acids. The shift from fatty acid oxidation to ketone body utilization may enhance cardiac efficiency and reduce oxidative stress, potentially improving cardiac function and inhibiting adverse myocardial remodeling. The trial's comprehensive biomarker assessments will help elucidate these complex metabolic, neurohumoral, and hemodynamic interactions, providing valuable insights into the pathophysiology of HFrEF in the context of T2DM and informing strategies for optimizing SGLT2 inhibitor therapy in this high-risk population.

Previous evidence suggesting SGLT2 inhibition's favorable effects on autonomic/sympathetic function provides important context for the TARGET-HF trial's mechanistic focus. Case reports have shown increased I-123 MIBG heart-to-mediastinum ratios after therapy, retrospective studies in T2DM patients with vasovagal syncope have indicated improved autonomic balance, and clinical trials have assessed empagliflozin's effects using heart-rate variability parameters. However, these studies used heterogeneous populations and surrogate methods. The TARGET-HF trial advances this field by prospectively evaluating cardiac sympathetic activity with MIBG as a prespecified primary endpoint specifically in patients with both HFrEF and T2DM. This population experiences complex pathophysiological interactions involving insulin resistance, chronic inflammation, and oxidative stress, making them particularly vulnerable to adverse cardiovascular outcomes. SGLT2 inhibitors may offer unique therapeutic benefits by targeting multiple aspects of this network of metabolic abnormalities, and the TARGET-HF trial aims to clarify these complex interactions.

Could These Findings Transform Clinical Practice?

The results of the TARGET-HF trial could have significant implications for clinical practice. If tofogliflozin demonstrates improvements in cardiac sympathetic activity as measured by I-123 MIBG scintigraphy, this would provide mechanistic support for the observed clinical benefits of SGLT2 inhibitors in heart failure patients. Such findings could influence treatment algorithms and potentially expand the indications for SGLT2 inhibitors beyond their current applications. Additionally, the comprehensive biomarker evaluations may identify specific patient subgroups who derive particular benefit from SGLT2 inhibition, enabling more personalized treatment approaches. The trial's focus on a high-risk population with both HFrEF and T2DM addresses an important clinical need, as these patients often experience worse outcomes despite standard therapies. By elucidating the mechanisms underlying SGLT2 inhibitors' cardioprotective effects, the TARGET-HF trial contributes valuable knowledge to the field of heart failure management and may inform future research directions.

Could the mechanistic insights from the TARGET-HF trial influence how we stratify patients with HFrEF and T2DM for more intensive therapy? The trial's findings regarding cardiac sympathetic modulation might provide a physiological basis for prioritizing SGLT2 inhibitors in certain patient subgroups, particularly those with evidence of sympathetic hyperactivation. Furthermore, could I-123 MIBG scintigraphy emerge as a valuable tool for risk stratification and therapeutic monitoring in heart failure management? While currently primarily a research tool, demonstrating its utility in tracking therapeutic responses might support its integration into clinical practice algorithms. Additionally, how might the metabolic effects of SGLT2 inhibition—particularly the shift toward ketone body utilization—interact with other heart failure therapies that modulate different pathophysiological pathways? The TARGET-HF trial's comprehensive assessment of multiple biomarkers may provide insights into potential synergistic effects when SGLT2 inhibitors are combined with neurohormonal antagonists, potentially guiding optimal combination strategies for this challenging patient population.

Summary

The TARGET-HF trial investigates the cardioprotective mechanisms of tofogliflozin, an SGLT2 inhibitor, in patients with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus. While SGLT2 inhibitors have demonstrated cardiovascular benefits including reduced hospitalization and mortality, the precise mechanisms remain unclear. This prospective single-arm study administers tofogliflozin 20 mg daily for 24 weeks to 50 patients across five Japanese hospitals, using I-123 MIBG scintigraphy to measure cardiac sympathetic activity as the primary endpoint. The trial hypothesizes that tofogliflozin improves cardiac sympathetic function through multiple pathways including metabolic optimization, reduced inflammation, hemodynamic improvements, and enhanced cardiac energy metabolism via increased ketone body production. Secondary endpoints include comprehensive biomarker panels and echocardiographic parameters. The study's innovative approach focuses on sympathetic overactivation, a key pathophysiological feature of HFrEF contributing to disease progression. Results could provide mechanistic support for SGLT2 inhibitors' clinical benefits, potentially influencing treatment algorithms and enabling personalized therapy approaches for this high-risk population with complex pathophysiological interactions.